Abiraterone is effective in the treatment of metastatic desmoplasia-resistant prostate cancer, and bicalutamide is more effective in the treatment of patients with locally advanced prostate cancer without distant metastases. Abiraterone is mainly used to treat metastatic desmoplasia-resistant prostate cancer, newly diagnosed high-risk metastatic endocrine therapy-sensitive prostate cancer, including those who have not been treated with endocrine therapy or have been treated with endocrine therapy for a maximum of 3 months. Bicalutamide 50 mg daily is used in combination with luteinizing hormone-releasing hormone analogs or surgical orchiectomy in advanced prostate cancer, and 150 mg is used to treat patients with locally advanced prostate cancer without distant metastases. Some patients may experience hypokalemia, hypertension, and urinary tract infections when using abiraterone, and it is contraindicated in pregnant women, lactating women, those with severe hepatic impairment, and those who are allergic to the drug. Bicalutamide patients may experience diarrhea, nausea, vomiting, angina, heart failure, etc. It is prohibited for children, women, and patients who are allergic to the drug, and should not be used in combination with terfenadine, astemizole or cisapride. Use with caution in patients with moderate or severe liver damage. It is recommended that patients under the guidance of a doctor to strictly follow the instructions of the doctor to use the drug, not blindly use the drug or change the dose of the drug without authorization, so as not to cause adverse effects on the body.